Endothelium-mediated control of vascular tone: COX-1 and COX-2 products
Reads0
Chats0
TLDR
Since in most cases, the activation of TP receptors is the common downstream effector, selective antagonists of this receptor should curtail endothelial dysfunction and be of therapeutic interest in the treatment of cardiovascular disorders.Abstract:
Endothelium-dependent contractions contribute to endothelial dysfunction in various animal models of aging, diabetes and cardiovascular diseases. In the spontaneously hypertensive rat, the archetypal model for endothelium-dependent contractions, the production of the endothelium-derived contractile factors (EDCF) involves an increase in endothelial intracellular calcium concentration, the production of reactive oxygen species, the predominant activation of cyclooxygenase-1 (COX-1) and to a lesser extent that of COX-2, the diffusion of EDCF towards the smooth muscle cells and the subsequent stimulation of their thromboxane A2-endoperoxide TP receptors. Endothelium-dependent contractions are also observed in various models of hypertension, aging and diabetes. They generally also involve the generation of COX-1- and/or COX-2-derived products and the activation of smooth muscle TP receptors. Depending on the model, thromboxane A2, PGH2, PGF2α, PGE2 and paradoxically PGI2 can all act as EDCFs. In human, the production of COX-derived EDCF is a characteristic of the aging and diseased blood vessels, with essential hypertension causing an earlier onset and an acceleration of this endothelial dysfunction. As it has been observed in animal models, COX-1, COX-2 or both isoforms can contribute to these endothelial dysfunctions. Since in most cases, the activation of TP receptors is the common downstream effector, selective antagonists of this receptor should curtail endothelial dysfunction and be of therapeutic interest in the treatment of cardiovascular disorders.
LINKED ARTICLES
This article is part of a themed issue on Vascular Endothelium in Health and Disease. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue-3read more
Citations
More filters
Journal ArticleDOI
Endothelial dysfunction and vascular disease – a 30th anniversary update
TL;DR: It has become clear that nitric oxide itself, under certain conditions (e.g. hypoxia), can cause biased activation of soluble guanylyl cyclase leading to the production of cyclic inosine monophosphate rather than cGMP and hence causes contraction rather than relaxation of the underlying vascular smooth muscle.
Journal ArticleDOI
Macro- and microvascular endothelial dysfunction in diabetes
Yi Shi,Paul M. Vanhoutte +1 more
TL;DR: This reviews pays special attention to microRNAs and their modulatory role in diabetes‐induced vascular dysfunction and some therapeutic strategies for preventing and restoring diabetic endothelial dysfunction are highlighted.
Journal ArticleDOI
Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator.
TL;DR: Genetic and pharmacological interventions improve dysfunctional NO-mediated vasodilatations if protecting the supply of substrate and cofactors for endothelial NO synthase, preserving the presence and activity of the enzyme and reducing reactive oxygen species generation.
Journal ArticleDOI
Overview of Platelet Physiology: Its Hemostatic and Nonhemostatic Role in Disease Pathogenesis
TL;DR: It is elucidates that platelets are not that innocent as they keep showing and thus numerous novel platelet biomarkers are upcoming very soon in the field of clinical research which can be important for predicting and diagnosing disease state.
Journal ArticleDOI
The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid
Laetitia Dou,Marion Sallée,Claire Cerini,Stéphane Poitevin,Bertrand Gondouin,Noémie Jourde-Chiche,Karim Fallague,Philippe Brunet,Raymond Calaf,Bertrand Dussol,Bernard Mallet,Françoise Dignat-George,Stéphane Burtey +12 more
TL;DR: Serum IAA may be an independent predictor of mortality and cardiovascular events in patients with CKD and has prooxidant and proinflammatory effects in vitro and in cultured human endothelial cells.
References
More filters
Journal ArticleDOI
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
TL;DR: It is demonstrated that relaxation of isolated preparations of rabbit thoracic aorta and other blood vessels by ACh requires the presence of endothelial cells, and that ACh, acting on muscarinic receptors of these cells, stimulates release of a substance(s) that causes relaxation of the vascular smooth muscle.
Journal ArticleDOI
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
TL;DR: A balance between formation of anti- and pro-aggregatory substances by enzymes could also contribute to the maintenance of the integrity of vascular endothelium and explain the mechanism of formation of intra-arterial thrombi in certain physiopathological conditions.
Journal ArticleDOI
Cyclooxygenases 1 and 2
TL;DR: The discovery ofCOX-2 has made possible the design of drugs that reduce inflammation without removing the protective PGs in the stomach and kidney made by COX-1, which may not only be anti-inflammatory but may also be active in colon cancer and Alzheimer's disease.
Journal ArticleDOI
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
TL;DR: It is demonstrated that EDRF is protected from breakdown by superoxide dismutase (SOD) and Cu2+, but not by catalase, and is inactivated by Fe2+.
Journal ArticleDOI
A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.
TL;DR: It is found that a series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase mechanism involving free radical-catalyzed peroxidation of arachidonic acid, and that these prostanoids may participate as pathophysiological mediators in oxidant injury.